Atsena Reports Preclinical ATSN-301 Data for Usher Syndrome
Atsena Therapeutics reports preclinical data showing MYO7A expression and favorable safety for its dual AAV gene therapy ATSN-301.
Atsena Therapeutics reports preclinical data showing MYO7A expression and favorable safety for its dual AAV gene therapy ATSN-301.